Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT01460706 : Imaging Malignant Glioma With 68Ga-DOTATOC PET/CT
PhasePhase 2/Phase 3
AgesMin: 18 Years Max: 70 Years
Eligibility
Inclusion Criteria:

- Age: 18 to 70 years old

- Language spoken: Finnish or Swedish

- Performance status: Karnofsky score 70 or better or WHO performance status 2 or
better

- Supratentorial malignant glioma based on MRI imaging

- Supratentorial recurrent glioma based on MRI and/or [11C]methionine PET imaging

- Patients must be able to understand the meaning of the study and sign the appropriate
Ethical Committee approved informed consent documents in the presence of the
designated staff

Exclusion Criteria:

- Any medical or psychiatric condition that compromises the subject´s ability to
participate in the study

- Any other significant disease including liver or renal disease

- Pregnant or lactating women
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT01460706      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740